Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Arovella Therapeutics Limited (ASX:ALA)
ALERT: Price-sensitive ASX Announcement for ALA
Current share price for ALA : $0.050 -0.015 (-23.08%)+
Announcement
Release
27 Jul 2026 12:15PM
Price at Release
$0.065
Full Release
Summary
Arovella Therapeutics Limited has advanced its lead product, ALA-101, towards clinical evaluation for treating blood cancers. The product, part of Arovella's CAR-iNKT cell therapy platform, has achieved significant progress, including ethics approval for a Phase 1 clinical trial in Australia. The company also continues to develop ALA-105 for solid tumors, showing promising preclinical results. Financially, Arovella ended the quarter with $14.4 million in cash, indicating a strong position to continue its research and development activities. The quarter also saw changes in the board and executive leadership, enhancing the company's focus on strategic objectives.
Key Points
- ALA-101 received ethics approval for Phase 1 trial in blood cancers.
- ALA-105 shows promising preclinical results for solid tumors.
- Arovella ends quarter with $14.4 million in cash.
- Significant leadership changes in board and executive team.
- Focus on expanding CAR-iNKT platform to solid tumors and autoimmune diseases.
- Financial report shows net cash outflows of $2.3 million for operations.
- Company aims to start first patient dosing for ALA-101 in September 2026.
- Arovella hosted investor engagement activities to increase visibility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
